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Abstract Primary aldosteronism (PA) is the most common
cause of secondary hypertension, accounting for 10% of all
hypertension. Far from being benign, hypertension due to
PA is associated with high cardiovascular morbidity and
mortality. However, PA is still underdiagnosed in general
practice. Recent reports strongly recommend that identify-
ing patients with PA is cost-beneficial based on improved
cardiovascular outcomes afforded by specific surgical and
medical treatment. This review provides an update of PA
including controversial aspects of diagnosis and treatment.
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1 What is primary aldosteronism?
Primary aldosteronism (PA), also called primary hyper-
aldosteronism or Conn’s syndrome, is characterized by
overproduction of aldosterone mainly due to either a
unilateral adrenocortical adenoma (APA) or to idiopathic
bilateral adrenal hyperplasia (IHA). This excessive aldoste-
rone secretion, which is relatively autonomous from the
renin-angiotensin system and refractory to sodium loading,
suppresses plasma renin and typically causes hypertension,
sodium retention, and potassium excretion, which can lead
to hypokalemia, hypomagnesemia and metabolic alkalosis.
2 How common is PA?
There is uncertainty about how common PA actually is. It was
previously believed that the prevalence of PA was less than
1% of all hypertensive patients and that hypokalemia was
necessary for detection of PA [1, 2]. Some clinicians who still
believe that the prevalence of PA is very low think that there
may be no cost-benefit in routinely look for PA, and that
testing for PA should be done only when drug therapy fails
or young adults develop hypertension. However, using the
plasma aldosterone concentration (PAC) to plasma renin
activity (PRA) ratio (ARR) as the most reliable available
screening test, many prospective and cross-sectional studies
have shown that markedly increased detection rates for PA
could be up to 10% of hypertensive patients, with most PA
patients being normokalemic [3–8]. It is now widely
recognized that primary aldosteronism (PA) is much more
common than previously thought and that aldosterone excess
has blood pressure (BP)—independent adverse cardiovascular
and renal effects. These two major conceptual changes have
prompted a lot of studies which have provided evidence for the
role of PA in cardiovascular, renal andmetabolic morbidity, and
suggest that PA should be systematically diagnosed and treated.
3 In which patient groups should detection of PA
be recommended?
The Endocrine Society USA issued clinical guidelines for
the detection, diagnosis, and management of PA, which is a
common, treatable and potentially curable disease [8]. The
guidelines suggest measuring ARR to detect PA in patient
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groups with a high prevalence of PA, such as patients with
severe or resistant hypertension, hypokalemia, hypertension
with adrenal incidentaloma, early-onset hypertension and
cerebrovascular accident at young age. This recommendation
for selective detection acknowledges the costs associated
with ARR testing of all hypertensive patients. However, the
guidelines also suggest that the risk of missing or delaying
the diagnosis of PA should be considerd in other hyperten-
sive patients, as the consequences of this may be the later
development of more severe and resistant hypertension
resulting from failure to lower the level of aldosterone or
block its actions. Several investigators have reported that
duration of hypertension is a predictor of refractory
hypertension after adrenalectomy for APA [9–11], suggest-
ing that delayed diagnosis of PA may result in reduced
effects of specific treatment for PA. Saving medical costs to
detect PA might result in paying much higher costs due to
cardiovascular complications.
The Japan Endocrine Society show a diagnostic and
therapeutic guide on its homepage, which recommends that
PA should be suspected in all patients with hypertension,
especially untreated patients who are free from antihyper-
tensive drugs that affect the ARR, a recommendation which
recognizes the lower medical costs in Japan. β-blockers and
clonidine can raise ARR by decreasing PRA more
markedly than PAC; otherwise, ACE inhibitors (ACE-I),
angiotensin II receptor blockers (ARBs), diuretics including
spironolactone and dihydropyridine calcium channel blockers
(CCBs) tend to reduce ARR [12]. Screening for PA among the
newly diagnosed hypertensive patients is thus much easier.
The prevalence of PAwas reported to be 5.4% in 1,020 newly
diagnosed Japanese hypertensive patients [5], and the preva-
lence of APA alone was also reported to be 4.8% in 1,125
newly diagnosed Italian hypertensive patients [7]. If a patient
has resistant hypertension and suppressed PRA in spite of
treatment with ACE-Is (or ARBs), CCBs and thiazides
(or thiazide-like diuretics), the only physiological interpreta-
tion can be sodium retention due to PA. Nevertheless, in
severe or resistant hypertension, withdrawal or replacement of
antihypertensive drugs could be potentially harmful. Thus, we
would like to stress that detection of PA should be done in
mild or moderate stages of hypertension, preferably in newly
diagnosed hypertensive patients.
4 Is detection of PA beneficial for the patients?
The complexity of detection and diagnosis of PA has raised
questions concerning whether identifying PA patients is worth
all the procedures, and whether specific treatment for PA
reverses clinically meaningful excess in morbidity because of
cardiovascular complications any better than usual antihyper-
tensive therapy. Recent publications have answered these
questions and have strongly pointed towards the affirmative.
Patients with PA are at a higher risk for cardiovascular
morbidity and mortality than patients with essential hyperten-
sion (EH) matched for age, gender, and systolic and diastolic
BP. Stroke, angina, myocardial infarction, chronic cardiac
insufficiency and atrial fibrillation are obviously more com-
mon in patients with PA [13–16]. Furthermore, the excess in
cardiovascular morbidity of PA patients was reversed in the
long term after surgery and specific medical treatment [13].
Excessive aldosterone causes renal damage in patients with
PA, leading to higher urinary albumin excretion (UAE) than in
matched patients with EH [17, 18]. This higher UAE in PA
patients is associated with a state of glomerular hyper-
filtration resulting from aldosterone-induced sodium reten-
tion and volume expansion, and is reversed by unilateral
adrenalectomy in APA or by spironolactone treatment [18].
5 Is there any association between PA and metabolic
syndrome?
There is ongoing debate concerning whether there is an
association between PA and metabolic syndrome that would
explain the excess cardiovascular morbidity. The affirma-
tive reports suggest that metabolic syndrome is more
prevalent in patients with PA than in others [19] and that
metabolic abnormality in patients with APA improves after
surgery [20]. In contrast to these findings, a very recent
retrospective study found no difference in fasting glucose
levels, lipid profile or prevalence of diabetes between 460
patients with PA and 1363 controls with EH [21].
6 Confirmatory tests for PA
The Endocrine Society guidelines recommend that either the
oral salt-loading test (OSLT), saline infusion testing (SIT),
fludrocortisone suppression test or captopril challenge test
(CCT) should be performed to confirm PA in patients with an
elevated ARR under conditions of minimum pharmacological
effects on the renin-angiotensin-aldosterone system [8]. These
four tests may differ in terms of sensitivity, specificity and
reliability. Therefore, the choice of a confirmatory test is
determined by cost, patient compliance and local expertise,
and still remains a matter of debate [19, 20]. The diagnostic
and therapeutic guide for PA from the Japan Endocrine
Society recommends three confirmatory tests: furosemide-
upright test (FUT), CCT and SIT. Of them, FUT used to be
performed in Japan, but it has a slightly lower sensitivity and
specificity and may involve considerable physical stress, and
now widely replaced by CCT, which can be performed in the
outpatient clinic thanks to its simplicity [22] although there is
a controversial report [23].
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7 Subtype differentiation of PA
The key diagnostic step in patients who want to pursue a
surgical cure for PA is to distinguish between unilateral
and bilateral aldosterone hypersecretion. Many reports
suggest that despite recent advances in imaging technol-
ogy, small APA may not be detectable on adrenal-
directed computed tomography (CT) or magnetic reso-
nance imaging (MRI), and that adrenal non-functioning
incidentalomas may coexist with IHA [24–27]. A very
recent meta-analysis of subtype differentiation of PA by
adrenal venous sampling (AVS), and CTor MRI, concluded
that imaging did not detect laterality of hyperaldosteronism in
37.8% of the cases based on the data from 950 PA patients in
38 reports when AVS was used as the standard test for
localization and diagnosis [28]; clinical decisions based
solely on imaging methods can thus lead to inappropriate
treatment. Although AVS is the gold standard for localization
of hyperaldosteronism, the lack of standardized protocols
and the other low rate of successful cannulation continue to
be challenging issues.
8 New strategies involving specific medical treatment
for PA
Eplerenone, a selective mineralocorticoid antagonist, has
been reported to be as effective as spironolactone in
reducing BP in patients with PA without sex steroid-
related side effects [29]. Eplerenone, at approximately 50
cents (US) for a 25 mg tablet in Japan, is now widely used
to treat patients with PA in Japan with some restrictions.
Hopefully, the usage of eplerenone for PA may soon be
considered in other countries where usage is less common.
Specific aldosterone synthase inhibitors currently under
phase II clinical trials may become a new treatment
modality for PA without inhibiting production of cortisol
or sex steroids [30].
9 Perspectives
Given the large number of patients with PA, comprehensive
screening programs and referral to specific centers need to
be developed by an interested group of endocrinologists,
hypertension specialists, internists, radiologists and surgeons
within each local community.
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